Latest news

Mexico becomes first country to approve H3 Pharma´s Sanvar® for esophageal variecal bleeding and four other indications

Debiopharm´s Eloxatin® (Oxaliplatin) awarded Prix Galien in France for innovative cancer therapy

Debiopharm exercises its Option and signs a License Agreement with the Shanghai Institute of Materia Medica for the Development and…

Debiopharm´s Pamorelin Long Acting, Formulated Using Debio® PLGA Technology, receives Final Marketing Autorisation in Germany

Yakult Honsha files Initial Submission for Marketing Authorisation of Debiopharm´s Oxaliplatin in Japan

H3 Pharma Inc. Submits new drug application to FDA for Sanvar® IR

Dyax Corp. and Debiopharm S.A. report positive Results from Phase IIa Clinical Trial with DX-890 (EPI-hNE4) in Children with Cystic…

ELOXATIN™ submitted in the United States and in Europe for the adjuvant treatment of patients with colon cancer

Eloxatin™ (oxaliplatin for injection) approved in the United States for the 1st line treatment of metastatic colorectal cancer